COMPETING INTERESTS: Dr. Graham has been an advisory board member for BMS, EMD Serono, Ipsen, Merck, and Pfizer. Dr. Basappa has been an advisory board member for AstraZeneca, Bayer, BMS, Eisai, EMD Serono, Ipsen, Janssen, Merck, Pfizer, Seagen, and Takeda; and has received a research grant from Ipsen. Dr. Bhindi has been an advisory board member for Bayer, EMD Serono, Ferring, Janssen, and Verity; has been a speaker (with honoraria) for Bayer, Merck, and Pfizer; and has participated in clinical trials supported by Bayer, Elypta AB, and Janssen. Dr. Bossé has been an advisory board member and given talks for AstraZeneca, Bayer, BMS, EMD Serono, Ipsen, Janssen, Knight Therapeutics, Merck, and Pfizer; and has received a grant from Ipsen. Dr. Canil has been an advisory board member for Advanced Accel, Bayer, BMS, Eisai, EMD Serono, Ipsen, Merck, Novartis, Pfizer, and Seagen; a speaker for EMD Serono and Pfizer; has received a grant from Janssen; and has participated in clinical trials supported by Eisai and Pfizer. Dr. Castonguay has been an advisory board member for Astellas, AstraZeneca, Bayer, BMS, Eisai, GSK, Ipsen, Janssen, and Merck; and has received payment from Astellas, AstraZeneca, Bayer, GSK, Ipsen, Janssen, Merck, and Tolmar. Dr. Heng has attended advisory board/consultancy meetings for BMS, Eisai, Exilexis, Ipsen, Merck, Novartis, and Pfizer. Dr. Inman has been an advisory board member for Abbvie, Combat Medical, Johnson & Johnson, Seattle Genetics, and TerSera; has received grants from National Institutes of Health, Department of Defense, TerSera, and Tolmar; and has participated in clinical trials supported by CG Oncology, FKD Therapies, Genentech-Roche, Janssen, Medtronic, Profound Medical, Seattle Genetics, and Theralase. Dr. Kollmannsberger has participated in advisory boards for Astellas, Bayer, BionTech, BMS, Eisai, Ipsen, Janssen, Merck, Novartis, Pfizer, and Seagen; has received speaker honoraria from Astellas, Bayer, BionTech, BMS, Eisai, Ipsen, Janssen, Merck Novartis, Pfizer, and Seagen; and has participated in several clinical trials (with no compensation). Dr. Lalani has received honoraria for ad hoc consulting from AbbVie, Astellas, AstraZeneca, Bayer, BMS, Eisai, EMD Serono, Ipsen, Janssen, McKesson, Merck, Novartis, Pfizer, Roche, and TerSera; and has participated in clinical trials supported by BMS, BioCanRx, EMD Serrono, Ipsen, Novartis, and Roche, with all funding to institution. Dr. Lavallée has been an advisory board member for Knight Therapeutics; and has received a grant from Tolmar. Dr. Msaouel has received honoraria for advisory boards membership for BMS, Exelixis, and Mirati Therapeutics; has received consulting fees from Axiom Healthcare; has participated in non-branded educational programs supported by Exelixis and Pfizer; holds a leadership or fiduciary role as a Medical Steering Committee member for the Kidney Cancer Association and a Kidney Cancer Scientific Advisory Board member for KCCure; and has received research funding from BMS, Gateway for Cancer Research, Mirati Therapeutics, and Takeda. Dr. Soleimani has received speaker honoraria from Bayer, Ipsen, and Pfizer; and is a medical advisor for Canadian VHL Alliance. Dr. Tanguay has been an advisory board member for Merck and TerSera. Dr. Richard has been an advisory board member for Astellas, Bayer, and Novartis; has received speaker honoraria from Abbvie, Astellas, Bayer, Janssen, Knight, Novartis, and Tolmar; and has participated in clinical trials supported by Merck. Dr. Alimohamed has been an advisor/consultant for AstraZeneca, Bayer, BMS, EMD Serono, Gilead, Merck, Pfizer, and Seagen. Dr. Kassouf has been participated as consultant on advisory boards for Abbvie, Astellas, Bayer, BMS, EMD Serono, Ferring, Janssen, Merck, Roche, and Sesen Bio; and has participated in clinical trials supported by Astra Zeneca, BMS, Janssen, Pfizer, Sesen Bio, and Theralase. Dr. Noonan has been and advisory bord member for AstraZeneca, Astellas, BMS, EMD Serono, Merck, Pfizer, Roche, and TerSera. The remaining authors and reviewers do not report any competing personal or financial interests related to this work.